Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

C2269000

Clindamycin phosphate

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Clindamycin 2-phosphate, Clindamycin 2-dihydrogen phosphate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H34ClN2O8PS
CAS Number:
24729-96-2
Molecular Weight:
504.96
EC Number:
246-433-0
MDL number:
MFCD07793328
UNSPSC Code:
41116107
PubChem Substance ID:
329774986
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

clindamycin

manufacturer/tradename

EDQM

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC([C@H](C)Cl)C2O[C@H](SC)[C@H](OP(O)(O)=O)[C@@H](O)[C@H]2O

InChI

1S/C18H34ClN2O8PS/c1-5-6-10-7-11(21(3)8-10)17(24)20-12(9(2)19)15-13(22)14(23)16(18(28-15)31-4)29-30(25,26)27/h9-16,18,22-23H,5-8H2,1-4H3,(H,20,24)(H2,25,26,27)/t9-,10+,11-,12?,13+,14-,15?,16+,18+/m0/s1

InChI key

UFUVLHLTWXBHGZ-MWBQRTRKSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Clindamycin phosphate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Spectrum of Activity: Gram positive cocci and taxoplasma. Especially active against anaerobic bacteria.
Mode of Action: Inhibits protein synthesis in bacterial by binding the 50s ribosomal subunit.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Antibacterial and antiprotozoal antibiotic of the licosamide class.
Sales restrictions may apply.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H317,H319,H362

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Lact. - Skin Sens. 1

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

M Badawy Abdel-Naser et al.
Expert opinion on pharmacotherapy, 9(16), 2931-2937 (2008-10-22)
Clindamycin phosphate 1.2% together with tretinoin 0.025% as a gel (CTG) is a topical formulation of a fixed and stable combination approved by the FDA for the treatment of acne vulgaris in patients 12 years of age or older. The
Diane Thiboutot et al.
Journal of the American Academy of Dermatology, 59(5), 792-800 (2008-09-23)
We sought to evaluate efficacy, safety, and tolerability of a combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% (clindamycin-BPO 2.5%) aqueous gel in moderate to severe acne vulgaris. A total of 2813 patients, aged 12 years or older, were
Lawrence F Eichenfield et al.
Pediatric dermatology, 26(3), 257-261 (2009-08-27)
Treatments for mild to moderately severe acne usually combine retinoid and antimicrobial therapy. Recently, the US FDA approved the combination of 1.2% clindamycin (CLIN) and 0.025% tretinoin (RA) in a novel gel formulation for the treatment of mild to moderate
Azadeh Ghaffari et al.
International wound journal, 9(2), 221-229 (2011-12-08)
Ethanol that affects hydration of skin and used in wound treatment formulations was studied here for its effect on permeation of drugs through burn eschar and to investigate the presence of a porous pathway in this barrier. In this study
C Hascicek et al.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 77(1), 116-121 (2010-11-23)
The aim of this work was to study the clindamycin release kinetics from floating delivery systems consisting of two modules assembled in void configuration, according to the modified release technology platform known as Dome Matrix®. Two modules differently shaped, i.e.
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service